These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 11418309)

  • 1. In vivo transfection and/or cross-priming of dendritic cells following DNA and adenoviral immunizations for immunotherapy of cancer--changes in peripheral mononuclear subsets and intracellular IL-4 and IFN-gamma lymphokine profile.
    Mincheff M; Altankova I; Zoubak S; Tchakarov S; Botev C; Petrov S; Krusteva E; Kurteva G; Kurtev P; Dimitrov V; Ilieva M; Georgiev G; Lissitchkov T; Chernozemski I; Meryman HT
    Crit Rev Oncol Hematol; 2001; 39(1-2):125-32. PubMed ID: 11418309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer: a phase I/II clinical trial.
    Mincheff M; Tchakarov S; Zoubak S; Loukinov D; Botev C; Altankova I; Georgiev G; Petrov S; Meryman HT
    Eur Urol; 2000 Aug; 38(2):208-17. PubMed ID: 10895014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
    Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
    Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generation of human dendritic cells that simultaneously secrete IL-12 and have migratory capacity by adenoviral gene transfer of hCD40L in combination with IFN-gamma.
    Knippertz I; Hesse A; Schunder T; Kämpgen E; Brenner MK; Schuler G; Steinkasserer A; Nettelbeck DM
    J Immunother; 2009 Jun; 32(5):524-38. PubMed ID: 19609245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules.
    Morse MA; Clay TM; Hobeika AC; Osada T; Khan S; Chui S; Niedzwiecki D; Panicali D; Schlom J; Lyerly HK
    Clin Cancer Res; 2005 Apr; 11(8):3017-24. PubMed ID: 15837756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA vaccine for cancer immunotherapy.
    Yang B; Jeang J; Yang A; Wu TC; Hung CF
    Hum Vaccin Immunother; 2014; 10(11):3153-64. PubMed ID: 25625927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells.
    Koido S; Hara E; Homma S; Torii A; Toyama Y; Kawahara H; Watanabe M; Yanaga K; Fujise K; Tajiri H; Gong J; Toda G
    Clin Cancer Res; 2005 Nov; 11(21):7891-900. PubMed ID: 16278414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
    Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
    Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Naked DNA immunization as an approach to target the generic tumor antigen survivin induces humoral and cellular immune responses in mice.
    Lladser A; Párraga M; Quevedo L; Carmen Molina M; Silva S; Ferreira A; Billetta R; G Quest AF
    Immunobiology; 2006; 211(1-2):11-27. PubMed ID: 16446167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trial.
    Cappuccini F; Bryant R; Pollock E; Carter L; Verrill C; Hollidge J; Poulton I; Baker M; Mitton C; Baines A; Meier A; Schmidt G; Harrop R; Protheroe A; MacPherson R; Kennish S; Morgan S; Vigano S; Romero PJ; Evans T; Catto J; Hamdy F; Hill AVS; Redchenko I
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32591433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides.
    Kavanagh B; Ko A; Venook A; Margolin K; Zeh H; Lotze M; Schillinger B; Liu W; Lu Y; Mitsky P; Schilling M; Bercovici N; Loudovaris M; Guillermo R; Lee SM; Bender J; Mills B; Fong L
    J Immunother; 2007 Oct; 30(7):762-72. PubMed ID: 17893568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Developing dendritic cell polynucleotide vaccination for prostate cancer immunotherapy.
    Berlyn KA; Ponniah S; Stass SA; Malone JG; Hamlin-Green G; Lim JK; Cottler-Fox M; Tricot G; Alexander RB; Mann DL; Malone RW
    J Biotechnol; 1999 Aug; 73(2-3):155-79. PubMed ID: 10486925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modification of human embryonic stem cell-derived dendritic cells with mRNA for efficient antigen presentation and enhanced potency.
    Nishimoto KP; Tseng SY; Lebkowski JS; Reddy A
    Regen Med; 2011 May; 6(3):303-18. PubMed ID: 21548736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Electroporation as a "prime/boost" strategy for naked DNA vaccination against a tumor antigen.
    Buchan S; Grønevik E; Mathiesen I; King CA; Stevenson FK; Rice J
    J Immunol; 2005 May; 174(10):6292-8. PubMed ID: 15879128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dendritic cell immunizations alone or combined with low doses of interleukin-2 induce specific immune responses in melanoma patients.
    Escobar A; López M; Serrano A; Ramirez M; Pérez C; Aguirre A; González R; Alfaro J; Larrondo M; Fodor M; Ferrada C; Salazar-Onfray F
    Clin Exp Immunol; 2005 Dec; 142(3):555-68. PubMed ID: 16297169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunization of colorectal carcinoma patients with a recombinant canarypox virus expressing the tumor antigen Ep-CAM/KSA (ALVAC-KSA) and granulocyte macrophage colony- stimulating factor induced a tumor-specific cellular immune response.
    Ullenhag GJ; Frödin JE; Mosolits S; Kiaii S; Hassan M; Bonnet MC; Moingeon P; Mellstedt H; Rabbani H
    Clin Cancer Res; 2003 Jul; 9(7):2447-56. PubMed ID: 12855617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity of dendritic cells pulsed with CEA peptide or transfected with CEA mRNA for vaccination of colorectal cancer patients.
    Lesterhuis WJ; De Vries IJ; Schreibelt G; Schuurhuis DH; Aarntzen EH; De Boer A; Scharenborg NM; Van De Rakt M; Hesselink EJ; Figdor CG; Adema GJ; Punt CJ
    Anticancer Res; 2010 Dec; 30(12):5091-7. PubMed ID: 21187495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dendritic cell vaccination of patients with metastatic colorectal cancer.
    Burgdorf SK
    Dan Med Bull; 2010 Sep; 57(9):B4171. PubMed ID: 20816019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor effect of dendritic cells transfected with prostate-specific membrane antigen recombinant adenovirus on prostate cancer: An in vitro study.
    Meng FD; Wang S; Jiang YH; Sui CG
    Mol Med Rep; 2016 Mar; 13(3):2124-34. PubMed ID: 26783185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.